Paul Scigalla

Biography

A physician and medical researcher with more than 30 years of experience in clinical oncology product development, Dr. Paul Scigalla joined Genelux Corporation in September 2011 as the company’s Chief Medical Officer. He is responsible for providing strategic direction of the company’s Clinical Program to secure expeditious market approval for current and future investigational product candidates. A native of Germany, Paul Scigalla received his medical training at Humboldt University in Berlin, graduating in 1970. After a fellowship in pediatric nephrology, Dr. Scigalla specialized in anemia in children with end-stage renal failure, earning his Ph.D. for research in the regulatory mechanism of erythropoiesis in end-stage renal failure in 1982. After 14 years in academic clinical practice, principally spent at the Pediatric Clinic of the Free University in Berlin, Dr. Scigalla entered the pharmaceutical industry in 1984. As head of Clinical Research for nephrology, oncology and bone metabolism at Boehringer Mannheim GmbH, he was responsible for the preclinical and clinical development of erythropoietin (licensed from Genetics Institute). This compound received licensing approval in Europe in 1988, only six years following discovery of the protein. In 1992, Dr. Scigalla was appointed Professor of Medicine at the University of Heidelberg. He later served as Boehringer Mannheim Senior Vice President and head of Global Development Therapeutics. Amongst many projects, he coordinated the development of ibandronate, a bisphosphonates for the treatment of bone metastases. Since leaving Boehringer Mannheim in 1998, Dr. Scigalla served as Senior Vice President at SUGEN, Inc., responsible for the clinical development of multiple receptor tyrosine kinase inhibitors, including semaxanib (currently in late-stage clinical trials for the treatment of cancer) and as Vice President Research Oncology, Pfizer Bedminster, New Jersey. Since August 2003, he has served as a consultant to several pharmaceutical companies in US, Japan and Europe. Dr. Scigalla has published over 200 manuscripts in scientific journals and served as editor of 8 books focused on pediatric nephrology and erythropoiesis. Prof. Scigalla has major interests in the clinical development of novel biologically-targeted therapies.

Research Interest

Medical Devices